Abstract:Background Despite being the second most common tumor in men worldwide, the tumor metabolism-associated mechanisms of prostate cancer (PCa) remain unclear. Herein, this study aimed to investigate the metabolism-associated characteristics of PCa and to develop a metabolism-associated prognostic risk model for patients with PCa. Methods The activity levels of PCa metabolic pathways were determined using mRNA expression profiling of The Cancer Genome Atlas Prostate Adenocarcinoma cohort via single-sample gene set enrichment analysis (ssGSEA). The analyzed samples were divided into three subtypes based on the partitioning around medication algorithm. Tumor characteristics of the subsets were then investigated using t-distributed stochastic neighbor embedding (t-SNE) analysis, differential analysis, Kaplan–Meier survival analysis, and GSEA. Finally, we developed and validated a metabolism-associated prognostic risk model using weighted gene co-expression network analysis, univariate Cox analysis, least absolute shrinkage and selection operator, and multivariate Cox analysis. Other cohorts (GSE54460, GSE70768, genotype-tissue expression, and International Cancer Genome Consortium) were utilized for external validation. Drug sensibility analysis was performed on Genomics of Drug Sensitivity in Cancer and GSE78220 datasets. In total, 1,039 samples and six cell lines were concluded in our work. Results Three metabolism-associated clusters with significantly different characteristics in disease-free survival (DFS), clinical stage, stemness index, tumor microenvironment including stromal and immune cells, DNA mutation ( TP53 and SPOP ), copy number variation, and microsatellite instability were identified in PCa. Eighty-four of the metabolism-associated module genes were narrowed to a six-gene signature associated with DFS, CACNG4 , SLC2A4 , EPHX2 , CA14 , NUDT7 , and ADH5 (p <0.05). A risk model was developed, and external validation revealed the strong robustness our risk model possessed in diagnosis and prognosis as well as the association with the cancer feature of drug sensitivity. Conclusions The identified metabolism-associated subtypes reflected the pathogenesis, essential features, and heterogeneity of PCa tumors. Our metabolism-associated risk model may provide clinicians with predictive values for diagnosis, prognosis, and treatment guidance in patients with PCa.

Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes

Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status

Identification of molecular subtypes and a prognostic signature based on chromatin regulators related genes in prostate cancer

An NMR-based metabolic signature to identify clinically significant prostate cancer in patients undergoing biopsy

Identification of characteristic metabolic panels for different stages of prostate cancer by 1H NMR-based metabolomics analysis

Identification of characteristic metabolic panels for different stages of prostate cancer by H-1 NMR-based metabolomics analysis

Metabolomic Footprints of Lethal Versus Indolent Prostate Cancer

Distinct Metabolic Signatures of Hormone-Sensitive and Castration-Resistant Prostate Cancer Revealed by a <SUP>1</SUP>H NMR-Based Metabolomics of Biopsy Tissue

Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model

Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles.

NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer

Precise diagnosis and risk stratification of prostate cancer by comprehensive serum metabolic fingerprints: A prediction model study

Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score

Epigenetic profiling of prostate cancer reveals potential prognostic signatures

Gene Expression Profiling Identifies Clinically Relevant Subtypes Of Prostate Cancer

GC-MS-based Metabolomics Reveals New Biomarkers to Assist the Differentiation of Prostate Cancer and Benign Prostatic Hyperplasia.

Metabolic heterogeneity signature of primary treatment-naïve prostate cancer

Metabolic Profiling of Prostate Cancer Tissue Using Magnetic Resonance Spectroscopy - An investigation into prostate heterogeneity and cancer characteristics in a transgenic mouse model, with a comparison to human disease

Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation

A novel prostate cancer subtyping classifier based on luminal and basal phenotypes

Metabolomic Analyses Redefine the Biological Classification of Pancreatic Cancer and Correlate with Clinical Outcomes